The Wall Street Journal reported Sunday that GlaxoSmithKline is allegedly being investigated over unethical behavior in the Middle East. The WSJ says it has seen emails with allegations that track closely with previous allegations of improper behavior in China that plagued the company over the last year.
An inside source tells the paper that he believes GSK “practices in Iraq violate the FCPA and the UK Bribery Act.” FCPA refers to the US Foreign Corrupt Practices Act. Allegations include paying government-supported healthcare providers to double as sales representatives and providing “high fees…in exchange for promoting and prescribing its drugs.”
